Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
about
Metalloproteinase inhibitors: status and scope from marine organismsDeep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspectiveProteasome inhibitors in progressive renal diseasesMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingDiscovery and development of the anticancer agent salinosporamide A (NPI-0052).A multi-parameter, high-content, high-throughput screening platform to identify natural compounds that modulate insulin and Pdx1 expression.Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathwaySalinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genesInhibiting NF-κB activation by small molecules as a therapeutic strategy.Modification of cysteine 179 of IkappaBalpha kinase by nimbolide leads to down-regulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agentsReactive oxygen species and autophagy modulation in non-marine drugs and marine drugs.Advances in and applications of proteasome inhibitorsProteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideCancer-linked targets modulated by curcuminMarine-derived angiogenesis inhibitors for cancer therapy.Treatment of follicular non-Hodgkin's lymphoma: the old and the new.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsPediatric developmental therapies: interesting new drugs now in early-stage clinical trials.New proteasome inhibitors in myeloma.Synthesis and pharmacology of proteasome inhibitors.Finding chemo: the search for marine-based pharmaceutical drugs active against cancer.Microbial natural products: molecular blueprints for antitumor drugs.Anticancer agent-based marine natural products and related compounds.Reveromycin A-Induced Apoptosis in Osteoclasts Is Not Accompanied by Necrosis.Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4.Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
P2860
Q21296828-5D9D6509-EC59-4571-9357-96506F7B47EEQ26776294-2A7BA208-F395-48D9-86F4-A9663186D6F5Q27011485-6C78A8AF-97F6-4B1A-A88C-ACFA75F66168Q28082335-3296825A-4F28-439A-AEBF-0635E6554DF8Q33622960-29E8351D-CA37-456C-B8E0-94294469E907Q33707607-B4846247-3DBF-4C53-A3FB-1C4D6DFC1C9AQ33862058-A43FC0C6-ED24-4CDA-8EB1-51506048D521Q34142223-C5B44A62-646E-47A2-B859-36A8385EB2E1Q34203659-74653A65-F84C-4183-8086-F708ADDA8AFAQ34205025-4FAD738E-9994-4F30-AF61-FD851087DF68Q34285044-1D54326E-58F5-4660-805E-BACA9AAB5B0EQ34577847-F2EA9F15-E181-4DD6-ABB6-8CCD8DD97CE6Q34594744-A016A761-CDEE-4390-AD3D-6C94ABF50DD8Q35989980-77679CF8-DCA2-4DB9-B795-553A71FBC7EEQ36499048-54732DF1-8FDC-4AE8-BC49-C0ABF16430E4Q36994177-ED42D107-9183-4714-ABB1-97319D81EAA9Q37003459-F5533682-453D-4064-938C-829423528FBFQ37017342-99406887-66A8-410F-B13B-9A2F6CA6DD7CQ37301320-677F1DDC-54FE-4E8D-AFAB-877385A9FC04Q38052079-5FF2BF91-BEEC-41BF-94DC-78158DBCEB3CQ38092777-1D0ABC04-821E-4E2B-B9B2-44152D49E001Q38127449-3E37D0C8-8081-4999-9F16-E6B9870EB287Q38133765-4E64C891-41B5-45AB-B194-F27241A4D98BQ38307526-EB3E4298-04EB-481B-8AB0-093D7D4FFC31Q38901830-85448EDA-64DC-4766-8F7D-DE8005F939A1Q39402696-530EE31A-2BDE-4A0E-83E0-620D77C47781Q39443721-4D661853-E6B5-4B7D-9388-3AFF64A223D4Q39990380-42730156-D62F-43C6-BF33-4AC33E458A12
P2860
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@ast
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@en
type
label
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@ast
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@en
prefLabel
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@ast
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@en
P2093
P2860
P1433
P1476
Salinosporamide A (NPI-0052) p ...... appaB regulated gene products.
@en
P2093
Anas Younes
Bharat B Aggarwal
Gautam Sethi
Kwang Seok Ahn
Madan M Chaturvedi
Michael A Palladino
Saskia T C Neuteboom
Ta-Hsiang Chao
P2860
P304
P356
10.1182/BLOOD-2007-04-084996
P407
P577
2007-07-03T00:00:00Z